NRG1 Fusion clinical trials at UC Cancer
2 research studies open to eligible people
Showing trials for
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion
open to eligible people ages 18 years and up
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.
at UC Irvine
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
open to eligible people ages 18 years and up
Open-label, Phase 2, single treatment arm, 3 cohorts
at UC Irvine UCSF
Last updated: